---
format:
  revealjs:
    touch: true
    controls: true
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: false
    incremental: true
    multiplex: true
    chalkboard: true
    theme: [default, custom.scss]
bibliography: references.bib
---

## Pros and Cons of Currently Approved Antifungals {background-image="antifungal_structures.png"}

<br> <br> <br> <br> <br> <br> <br> <br> <br>

<center>Russell E. Lewis, Pharm.D., FCCP <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Medical and Surgical Sciences <br> University of Bologna</center>

## Antifungal timeline

<br>

```{r}
library(readxl)
timeline <- read_excel("timeline.xlsx", col_types = c("text", "date", "text", "text", "text", "text"))
library (vistime)
vistime (timeline, 
         col.event = "event",
         col.start = "start",
         col.group = "group",
         col.color = "color",
         col.fontcolor = "fontcolor",
         col.tooltip = "tooltip",
         optimize_y = TRUE,
         linewidth = NULL,
         title = NULL,
         show_labels = TRUE,
         background_lines = NULL)
```

## Antifungal mechanisms of action

![](mechanisms.png){fig-align="center"}

## Amphotericin B-deoxycholate: <br> The "historic" gold standard

![](AMB_chol_ergo.png){fig-align="center" width="800"}

## Amphotericin B: Mechanisms of action

<br>

![](AMB_MOA.png){fig-align="center" width="3000"}

## Amphotericin B: Spectrum of activity

<br>

![](Spectrum_AMB.png){fig-align="center"}

## Amphotericin B-Immunological effects

<br>

<br>

::: columns
::: {.column width="40%"}
![](AMB_immune.png){fig-align="center"}
:::

::: {.column width="60%"}
-   AMB directly activates Toll-like receptor 2 (TLR-2) in monocytic cells causing release of TNF-α, IL-1β, IL-6 and prostaglandin E2
-   Mechanism of infusion-related reactions (IRRs): fever, rigours, headache, nausea, vomiting, hypotension
-   IRR onset typically 2-6 hours after AMB infusion
:::
:::

## Amphotericin B nephrotoxicity

![](AMB_nephro_mech.png){fig-align="center"} IN 10 clinical trials, AMB-deoxycholate associated with \> 2 fold increased in SeCr in 26% of patients

::: aside
[@aguirre2013J]
:::

## Antifungal timeline

<br>

```{r}
library(readxl)
timeline <- read_excel("timeline.xlsx", col_types = c("text", "date", "text", "text", "text", "text"))
library (vistime)
vistime (timeline, 
         col.event = "event",
         col.start = "start",
         col.group = "group",
         col.color = "color",
         col.fontcolor = "fontcolor",
         col.tooltip = "tooltip",
         optimize_y = TRUE,
         linewidth = NULL,
         title = NULL,
         show_labels = TRUE,
         background_lines = NULL)
```

## Lipid formulations of amphotericin B

![](lipidform.png){fig-align="center"}

::: aside
[@aguirre2013J]
:::

## Liposomal amphotericin B summary {background-image="antifungal_structures.png"}
<br>

::: columns
::: {.column width="50%"}
**Established roles**

-   Empiric therapy in patients with prior echinocandin or triazole treatment
-   Directed therapy for triazole or echinocandin-resistant yeast or molds
-   Durg of choice for induction therapy for cryptococcal meningitis (with 5-FC/fluconazole backbone)
-   Initial drug of choice for severe endemic fungal infections, mucormycosis
-   "Bridge" therapy in patients who cannot take triazoles
-   Visceral leishmaniasis
:::

::: {.column width="50%"}
**Current limitations**

-   IRRs with AMB-deoxycholate, complement-activation related pseudoallergy (CARPA) reactions with L-AMB
-   Nephrotoxicity
-   Not an ideal "outpatient" drug for most infections
-   Limited drug distribution to urine
:::
:::

## References

<br>

All images were preapred by the author using www.biorender.com

<br>
